About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2025 Clareo Health. All rights reserved.

TERMINATEDPhase 1

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Phase I Trial of Fedratinib in Combination With Decitabine in Patients With Myeloproliferative Neoplasms in Accelerated and Blast Phase

NCT05524857•Joseph Jurcic

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Myeloproliferative Neoplasm

Interventions

Fedratinib Oral Capsule 300 mg

Decitabine 20 mg/m2

+1 more

Locations

1

United States

Locations (1)

New York Presbyterian Hospital/Columbia University Irving Medical Center

New York, New York, United States

Key Dates

Start Date

January 28, 2022

Primary Completion Date

April 9, 2024

Completion Date

April 9, 2024

Last Updated

April 23, 2024

Related Studies

RECRUITINGPhase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424

AML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)+9 more

RECRUITINGPhase 1

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

NCT07270978

Acute Myeloid LeukemiaMyelodysplastic Syndromes+1 more

RECRUITINGPhase 1/2

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT06523556

Atypical Chronic Myeloid LeukemiaChronic Myelomonocytic Leukemia+6 more

RECRUITINGPhase 2

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

NCT03970096

Acute LeukemiaAcute Lymphoblastic Leukemia+3 more

RECRUITINGPhase 1/2

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

NCT05123365

Myeloproliferative NeoplasmMPN+3 more

Evaluation of the Pathobiology of CALR-mutated MPN Cells

NCT06480591

Myeloproliferative Neoplasm

View all related studies

Sponsors

Lead Sponsor

Joseph Jurcic

Collaborators

Bristol-Myers Squibb

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 23, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions